These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16128165)

  • 1. [Obesity and metabolic syndrome: clinical and therapeutic review].
    Cuppini A; Matteini P
    Monaldi Arch Chest Dis; 2005 Mar; 64(1):45-9. PubMed ID: 16128165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The obesity epidemic and its cardiovascular consequences.
    Behn A; Ur E
    Curr Opin Cardiol; 2006 Jul; 21(4):353-60. PubMed ID: 16755205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome treatment strategies.
    Fujioka K
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):222S-226S. PubMed ID: 17125449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short- and long-term beneficial effects of a multidisciplinary therapy for the control of metabolic syndrome in obese adolescents.
    Caranti DA; de Mello MT; Prado WL; Tock L; Siqueira KO; de Piano A; Lofrano MC; Cristofalo DM; Lederman H; Tufik S; Dâmaso AR
    Metabolism; 2007 Sep; 56(9):1293-300. PubMed ID: 17697875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options for modifying cardiometabolic risk factors.
    Aronne LJ
    Am J Med; 2007 Mar; 120(3 Suppl 1):S26-34. PubMed ID: 17320519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
    Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
    Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating obesity in the family practice setting.
    Fernstrom MH
    Postgrad Med; 2001 Jun; 109(6 Suppl):10-8. PubMed ID: 19667563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The progression of cardiovascular risk to cardiovascular disease.
    Rosin BL
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S3-8. PubMed ID: 17934392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity.
    Park HS; Lee K
    Diabet Med; 2005 Mar; 22(3):266-72. PubMed ID: 15717873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The "problem obesity": viewpoint of the internist].
    Guagnano MT; Manigrasso MR; Capani F; Davì G
    Ann Ital Chir; 2005; 76(5):407-11. PubMed ID: 16696212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management.
    Neeland IJ; Poirier P; Després JP
    Circulation; 2018 Mar; 137(13):1391-1406. PubMed ID: 29581366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of body mass reduction on metabolic disorders and complications in patient with morbid obesity. Three years observation].
    Pietrzak-Nowacka M; Safranow K; Kedzierska K
    Pol Arch Med Wewn; 2005 Jun; 113(6):575-9. PubMed ID: 16454448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical strategies for weight loss in the overweight and obese patient.
    Di Caro S; Hamad GG; Fernstrom MH; Schauer PR; Bonanomi G
    Minerva Gastroenterol Dietol; 2006 Dec; 52(4):415-30. PubMed ID: 17108871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic options for metabolic syndrome in obese patients].
    Carella AM; Conte M
    Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN; Ribeiro Filho FF; Kohlmann NE; Gouvea Ferreira SR; Zanella MT
    Diabetes Obes Metab; 2005 May; 7(3):246-53. PubMed ID: 15811141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D; Diamanti-Kandarakis E; Katsikis I; Nassis GP; Karkanaki A; Georgopoulos N; Panidis D
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
    Georgopoulos NA; Katsikis I; Florakis D; Panidis D; Kandarakis ED
    Fertil Steril; 2009 Jun; 91(6):e1. PubMed ID: 19362719
    [No Abstract]   [Full Text] [Related]  

  • 19. [What effect does losing weight have on hypertension?].
    Engeli S
    MMW Fortschr Med; 2003 Jul; 145(27-28):44. PubMed ID: 14587188
    [No Abstract]   [Full Text] [Related]  

  • 20. A pilot study investigating the effect of Caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: a randomised controlled clinical trial.
    Astell KJ; Mathai ML; McAinch AJ; Stathis CG; Su XQ
    Complement Ther Med; 2013 Jun; 21(3):180-9. PubMed ID: 23642949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.